October 3, 2024 07:29 AM EDTUpdated 12:11 PM
Pharma

Eli Lil­ly re­solves short­age for tirzepatide, po­ten­tial­ly end­ing com­pounder­s' run

Ayisha Sharma

News Reporter

Eli Lil­ly’s block­buster GLP-1 drug tirzepatide is fi­nal­ly back on track in the US af­ter two years of in­ter­mit­tent short­ages dri­ven by high de­mand, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times